Page 5 - hypertension_newsletter_Special_Servier_final

REFLECTIONS
Hypertension
Hypertension Special Edition – ESH 2024 Highlights

Time to act to improve adherence in hypertension management: Bridging the gap
between knowledge and action.
Hypertension
Chair: Prof. Williams (United Kingdom), Prof. Burnier (Switzerland)
Presenters: Prof. Burnier (Switzerland), Prof. Pathak (France)

In the last symposium highlighted here, the focus was on
identifying the challenges for nonadherence, including watching
for warning signs such as inadequate response to treatment,
unexpected increases in BP in previously well-controlled
patients, complex treatment regimens, depression, and lack
of belief in benefits from the patients, which should all lead to
a high index of suspicion. Any solution must be looked at with
the eye of the patient. For example, if an SPC is prescribed, it
should be linked to communication about how this will reduce
BP , allow the patient to live longer, and avoid strokes or a heart
attack. This illustrates the importance of shared decision-making
and the trust the patient places with the physician. CLICK HERE
TO VIEW AN INTERVIEW WITH PROF.
CLICK HERE WILLIAMS ON HOW TO IMPROVE
TO VIEW THE RECORDING ADHERENCE IN HYPERTENSION
OF THE SYMPOSIUM MANAGEMENT. (3 MIN 58 SEC)

EPIDEMIOLOGY

Findings from May Measurement Month Campaign.

Awareness, treatment, and control of hypertension using opportunistic screening
programs: Evidence from the May Measurement Month campaign, 2017-2019.
Razo C, et al. J. Hypertens. 2024;42(Suppl 1):e24.

The objective of the study was to evaluate hypertension awareness in adults (>18 years), treatment, control, and comorbidities
using three years of May Measurement Month (MMM) data (2017–2019). Among 2,907,848 participants from 95 countries, 34.2%
had hypertension. Among those with hypertension, 60.1% were aware, 57.0% were medicated, 32.0% were controlled, and
22.8% had at least one additional chronic condition. Of those with hypertension who were on medication, 57.0% were controlled.
Data suggests heterogeneity in awareness, treatment, and control, and poorer hypertension management in individuals without
comorbidities, informing global strategies for improved hypertension prevention, detection, and management.

TABLE OF CONTENTS